PharVision Advisers LLC Purchases Shares of 33,326 Cryoport, Inc. (NASDAQ:CYRX)

PharVision Advisers LLC purchased a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 33,326 shares of the company’s stock, valued at approximately $259,000.

A number of other large investors also recently modified their holdings of CYRX. Cadian Capital Management LP grew its holdings in shares of Cryoport by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after purchasing an additional 609,021 shares during the period. Millennium Management LLC grew its stake in Cryoport by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock worth $32,208,000 after buying an additional 409,353 shares during the period. Deutsche Bank AG grew its stake in Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock worth $10,870,000 after buying an additional 12,864 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Cryoport by 8.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company’s stock worth $6,615,000 after acquiring an additional 63,301 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its stake in shares of Cryoport by 77.0% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company’s stock valued at $5,780,000 after acquiring an additional 323,216 shares during the period. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Cryoport Trading Down 8.9%

NASDAQ:CYRX opened at $6.14 on Thursday. The stock has a market cap of $307.84 million, a price-to-earnings ratio of -1.82 and a beta of 1.92. Cryoport, Inc. has a one year low of $4.58 and a one year high of $12.11. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The business’s 50-day simple moving average is $5.94 and its 200 day simple moving average is $6.85.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to the consensus estimate of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. As a group, sell-side analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 19,830 shares of company stock worth $118,353. Insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on CYRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Cryoport in a research report on Thursday, May 8th. Morgan Stanley decreased their target price on Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Monday, May 5th. UBS Group raised their target price on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Roth Mkm reissued a “buy” rating and set a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cryoport in a research report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Cryoport has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.